Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib vs Crizotinib in ALK+ Advanced Lung Cancer
NCT02737501Phase 3Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- May 2016
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by ARIAD Pharmaceuticals, Inc.. Started May 2016; status: completed.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02737501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737501.